Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$0.95 USD
-0.03 (-3.04%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VOR 0.95 -0.03(-3.04%)
Will VOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VOR
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
VOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
Other News for VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics appoints Nathan Jorgensen as CFO
Voyager Therapeutics appoints Jorgensen as CFO
Vor Biopharma Announces Interim Financial Leadership Changes
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)